Targeting DNA repair and the cell cycle in glioblastoma (Q37960389)

26 August 2017

Targeting DNA repair and the cell cycle in glioblastoma (English)

1 reference

26 August 2017

3

Patrick Y Wen

1 reference

26 August 2017

Brian M Alexander

1

1 reference

26 August 2017

Nancy Pinnell

series ordinal

2

1 reference

26 August 2017

Alan D'Andrea

series ordinal

4

1 reference

26 August 2017

language of work or name

1 reference

24 November 2011

1 reference

Journal of Neuro-Oncology

26 August 2017

1 reference

26 August 2017

107

1 reference

26 August 2017

3

1 reference

26 August 2017

463-477

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-011-0765-4

26 August 2017

0 references

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

A phylogenomic study of DNA repair genes, proteins, and processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The DNA damage response: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

New insights into checkpoint kinase 1 in the DNA damage response signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Interfaces between the detection, signaling, and repair of DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Cellular response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Quality control by DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The multifaceted mismatch-repair system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Subpathways of nucleotide excision repair and their regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

How nucleotide excision repair protects against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

DNA double-strand breaks: signaling, repair and the cancer connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The DNA replication fork in eukaryotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Emerging cancer therapeutic opportunities target DNA-repair systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Exploiting tumour hypoxia in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Targeting base excision repair for chemosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

A single ataxia telangiectasia gene with a product similar to PI-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Poly(ADP-ribose): novel functions for an old molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Molecular targeting of glioblastoma: Drug discovery and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Proteasome function is required for DNA damage response and fanconi anemia pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

New checkpoint blockers begin human trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Mechanism by which caffeine potentiates lethality of nitrogen mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Wee1+-like gene in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

GammaH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Mismatch correction at O 6 -methylguanine residues in E. coli DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0765-4

Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage

21 January 2018

1 reference

12 December 2020

Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization

1 reference

12 December 2020

DNA repair targeting and radiotherapy: a focus on the therapeutic ratio

1 reference

12 December 2020

WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity

1 reference

12 December 2020

Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity

1 reference

12 December 2020

Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells

1 reference

12 December 2020

Enhancing radiotherapy through a greater understanding of homologous recombination

1 reference

12 December 2020

S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.

1 reference

12 December 2020

The 2007 WHO classification of tumours of the central nervous system

1 reference

12 December 2020

Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle

1 reference

12 December 2020

The role of DNA mismatch repair in drug resistance.

1 reference

12 December 2020

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

1 reference

12 December 2020

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

1 reference

12 December 2020

Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas.

1 reference

12 December 2020

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

1 reference

12 December 2020

Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells

1 reference

12 December 2020

Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation.

1 reference

12 December 2020

Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

1 reference

12 December 2020

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

1 reference

12 December 2020

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.

1 reference

12 December 2020

The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress

1 reference

12 December 2020

Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification

1 reference

12 December 2020

Triazene compounds: mechanism of action and related DNA repair systems.

1 reference

12 December 2020

10.1007/S11060-011-0765-4

Identifiers

DOI

1 reference

release_qfwz2p7bwngbrde4hcmp24xo7y

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qfwz2p7bwngbrde4hcmp24xo7y

24 November 2022

mapped directly with Wikidata item

1 reference